Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: Improvement of potency in vitro and in vivo

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 3, 2011, Pages 904-908

  Shimizu, Hiroki ^a   Yasumatsu, Isao ^a   Hamada, Tomoaki ^a   Yoneda, Yoshiyuki ^a   Yamasaki, Tomonori ^a   Tanaka, Shinji ^a   Toki, Tadashi ^a   Yokoyama, Mika ^a   Morishita, Kaoru ^a   Iimura, Shin ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

IKK; Inhibitor; Interaction model; NF B; TNF

Indexed keywords

I KAPPA B KINASE INHIBITOR; IMIDAZO[1,2 B]PYRIDAZINE; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PYRIDAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BINDING SITE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG STABILITY; DRUG SYNTHESIS; IC 50; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN;

ANIMALS; BINDING SITES; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; I-KAPPA B KINASE; MALE; MICE; PROTEIN KINASE INHIBITORS; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 78751643410     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.12.078     Document Type: Article

References (33)

1. R. Sen, and D. Baltimore Cell 47 1986 921
2. Q. Li, and I.M. Verma Nat. Rev. Immunol. 2 2002 725
3. M.S. Hayden, and S. Ghosh Cell 132 2008 344
4. K.D. Brown, E. Claudio, and U. Siebenlist Arthritis Res. Ther. 10 2008 1
5. P. Viatour, M.P. Merville, V. Bours, and A. Chariot Trends Biochem. Sci. 30 2005 43
6. U. Senftleben, and M. Karin Crit. Care Med. 30 2002 S18
7. M. Karin, and A. Lin Nat. Immunol. 3 2002 221
8. L.M. Coussens, and Z. Werb Nature 420 2002 860
9. H.J. Kim, N. Hawke, and A.S. Baldwin Cell Death Differ. 13 2006 738
10. N.D. Perkins, and T.D. Gilmore Cell Death Differ. 13 2006 759
11. M. Asagiri, and H. Takayanagi Bone 40 2007 251
12. M.G. Ruocco, S. Maeda, J.-M. Park, T. Lawrence, L.-C. Hsu, Y. Cao, G. Schett, E.F. Wagner, and M. Karin J. Exp. Med. 201 2005 1677
13. P.P. Tak, and G.S. Firestein J. Clin. Invest. 107 2001 7
14. M.S. Hayden, and S. Ghosh Genes Dev. 18 2004 2195
15. H. Häcker, and M. Karin Sci. STKE 357 2006 re13
16. J.A. DiDonato, M. Hayakawa, D.M. Rothwarf, E. Zandi, and M. Karin Nature 388 1997 548
17. F. Mercurio, H. Zhu, B.W. Murray, A. Shevchenko, B.L. Bennett, J. Li, D.B. Young, M. Barbosa, M. Mann, A. Manning, and A. Rao Science 278 1997 860
18. J.D. Woronicz, X. Gao, Z. Cao, M. Rothe, and D.V. Goeddel Science 278 1997 866
19. M. Karin, Y. Yamamoto, and Q.M. Wang Nat. Rev. Drug Discovery 3 2004 17
20. S.M. Blake, and B.A. Swift Curr. Opin. Pharmacol. 4 2004 276
21. J.R. Burke, and J. Strnad Trends Pharmacol. Sci. 28 2007 142
22. H. Shimizu, S. Tanaka, T. Toki, I. Yasumatsu, T. Akimoto, K. Morishita, T. Yamasaki, T. Yasukochi, and S. Iimura Bioorg. Med. Chem. Lett. 20 2010 5113
23. Compound 1 showed more than 90% inhibition against three kinases (ALK, JAK2 and PKD2), and showed 80-90% inhibition against 6 kinases at 10 μM out of 250 kinases.
24. Compound 5d showed 80% inhibition against PKD3 at 0.2 μM out of 19 kinases in which compound 1 showed relatively strong inhibitory activity.
25. 2) was noted. The 3D structures were generated using CORINA (Molecular Networks GmbH) and optimized using MacroModel and PM3 method in the MOPAC 7 program. PSA values were calculated using VEGA.
26. 2, plasma was obtained by centrifugation (2000 rpm, 5 min, 4 °C). TNFα concentration in the plasma was measured by ELISA assay as described by the manufacturer's instructions (BD Bioscience).
27. Inhibition assay of LPS-induced TNFα production in mice. Male BALB/c mice (7-12 weeks old) were orally given a test compound or 0.5% methyl cellulose. Thirty min after treatment, 0.02 mg/kg of LPS in saline was administrated intravenously. One hour after the injection of LPS solution, blood was collected from inferior vena cava with heparin as an anticoagulant under ether anesthesia. Plasma was obtained by centrifugation (3000 rpm, 30 min, 4 °C) and immediately stored at -20 °C. TNFα concentration in the plasma was measured by ELISA assay as described by the manufacturer's instructions (R&D Systems).
28. A. Degterev, J. Hitomi, M. Germscheid, I.L. Ch'en, O. Korkina, X. Teng, D. Abbott, G.D. Cuny, C. Yuan, G. Wagner, S.M. Hedrick, S.A. Gerber, A. Lugovskoy, and J. Yuan Nat. Chem. Biol. 4 2008 313
29. Compound 7a showed 61% inhibition against PKD3 at 0.2 μM out of 19 kinases in which compound 1 showed relatively strong inhibitory activity.
30. G.S. Lal, G.P. Pez, R.J. Pesaresi, F.M. Prozonic, and H. Cheng J. Org. Chem. 64 1999 7048
31. Machinaga, N.; Chiba, J.; Hoh, H.; Nakayama, A.; Muro, F.; Yoneda, Y.; Iimura, S. WO2007069635, 2007.
32. M. Kunishima, C. Kawachi, F. Iwasaki, K. Terao, and S. Tani Tetrahedron Lett. 40 1999 5327
33. C. Herb, A. Bayer, and M.E. Maier Chem. Eur. J. 10 2004 5649